Summarized Science🧠Neuro Oncology Research Highlights - Mar 2026
• ERADECs outperform antibodies in PD-L1 degradation and tumor suppression
• STANM achieves 200-fold drug concentration increase at tumor sites
• Structural variants drive 60%+ of pediatric cancer mutations
• Trispecific macrophage engager boosts cytotoxicity against solid tumors
